X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (18) 18
index medicus (17) 17
pharmacology & pharmacy (15) 15
female (13) 13
male (12) 12
pharmacogenetics (10) 10
middle aged (9) 9
genotype (7) 7
risk factors (7) 7
toxicity (7) 7
adult (6) 6
polymorphism (6) 6
aged (5) 5
analysis (5) 5
drug therapy (5) 5
patients (5) 5
polymorphism, single nucleotide (5) 5
risk (5) 5
single nucleotide polymorphisms (5) 5
antiviral agents - adverse effects (4) 4
atrial fibrillation (4) 4
cancer (4) 4
chemotherapy (4) 4
gene (4) 4
hepatitis (4) 4
medical research (4) 4
medicine, experimental (4) 4
pharmacology/toxicology (4) 4
polymerase chain reaction (4) 4
alleles (3) 3
anemia (3) 3
antiviral agents - administration & dosage (3) 3
antiviral agents - therapeutic use (3) 3
biology (3) 3
biomedicine (3) 3
care and treatment (3) 3
chromosomes (3) 3
colorectal cancer (3) 3
deoxyribonucleic acid--dna (3) 3
dihydrouracil dehydrogenase - genetics (3) 3
fluoropyrimidines (3) 3
fluorouracil - adverse effects (3) 3
fluorouracil - therapeutic use (3) 3
gene expression (3) 3
genetic aspects (3) 3
genotype & phenotype (3) 3
hiv infections - genetics (3) 3
medicine & public health (3) 3
metabolism (3) 3
neurosciences (3) 3
physiological aspects (3) 3
prospective studies (3) 3
settore bio/14 - farmacologia (3) 3
single-nucleotide polymorphism (3) 3
stroke (3) 3
variants (3) 3
1st-line treatment (2) 2
5-fluorouracil (2) 2
abcb1 (2) 2
adolescent (2) 2
anemia - chemically induced (2) 2
antidepressants (2) 2
antineoplastic combined chemotherapy protocols - therapeutic use (2) 2
antiretroviral drugs (2) 2
association (2) 2
cancer patients (2) 2
capecitabine (2) 2
cell differentiation - genetics (2) 2
child (2) 2
chromatin (2) 2
chronic obstructive pulmonary disease (2) 2
colorectal neoplasms - drug therapy (2) 2
confidence intervals (2) 2
congenital, hereditary, and neonatal diseases and abnormalities (2) 2
cytochrome p-450 cyp3a - genetics (2) 2
depression (2) 2
dihydropyrimidine dehydrogenase (2) 2
dpyd (2) 2
drug therapy, combination (2) 2
drug therapy, combination - adverse effects (2) 2
enzymes (2) 2
equilibrative nucleoside transporter 1 - genetics (2) 2
expression (2) 2
fibrillation (2) 2
fluorouracil (2) 2
fluorouracil - administration & dosage (2) 2
gene frequency (2) 2
gene mapping (2) 2
gene polymorphism (2) 2
genes (2) 2
genetic factors (2) 2
genetic predisposition to disease (2) 2
genetics (2) 2
genomics (2) 2
genotypes (2) 2
genotyping (2) 2
glucuronosyltransferase - genetics (2) 2
health risks (2) 2
hepatitis c, chronic - drug therapy (2) 2
heterozygote (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical and Experimental Pharmacology and Physiology, ISSN 0305-1870, 02/2017, Volume 44, Issue 2, pp. 191 - 196
Journal Article
Journal Article
BMC infectious diseases, ISSN 1471-2334, 11/2018, Volume 18, Issue 1, pp. 556 - 8
BackgroundNevirapine has been used as antiretroviral agent since early 90. Although nevirapine is not currently recommended in initial anti-HIV regimens, its... 
Pharmacogenetic | ABCB1 | Nevirapine | Hepatotoxicity | POPULATION | INFECTIOUS DISEASES | MANAGEMENT | ADULTS | INDIVIDUALS | REVERSE-TRANSCRIPTASE INHIBITORS | PHARMACOKINETICS | PLASMA-CONCENTRATIONS | INFECTED PATIENTS | PHARMACOGENETICS | Severity of Illness Index | Genetic Predisposition to Disease | Anti-HIV Agents - adverse effects | HIV Infections - epidemiology | HIV Infections - genetics | Humans | Middle Aged | Risk Factors | Anti-Retroviral Agents - adverse effects | Chemical and Drug Induced Liver Injury - epidemiology | Male | Chemical and Drug Induced Liver Injury - genetics | Nevirapine - adverse effects | Anti-HIV Agents - administration & dosage | Drug Therapy, Combination - adverse effects | HIV | Anti-Retroviral Agents - administration & dosage | HIV Infections - complications | Adult | Female | HIV Infections - drug therapy | Retrospective Studies | Nevirapine - administration & dosage | Usage | Diagnosis | Hepatitis C virus | Cytochrome | Toxicity | Liver | Genomics | Single-nucleotide polymorphism | Gene polymorphism | Genotype & phenotype | Hepatitis | Regression models | Acquired immune deficiency syndrome--AIDS | Antiretroviral agents | Risk assessment | Human immunodeficiency virus--HIV | Population | Genetic factors | Drug therapy | Drug dosages | Genotypes | Immune system | Antiretroviral drugs | Enzymes | Equilibrium methods | Regression analysis | Metabolism | Gene expression | Minority & ethnic groups | Patients | Antiretroviral therapy | Studies | Infectious diseases | Genotyping | Gene mapping | Polymorphism
Journal Article
SAGE Open Medicine, ISSN 2050-3121, 6/2018, Volume 6, p. 2050312118780861
Background: Only few data are available on the influence of CYP2B6 and CYP3A4/A5 polymorphisms on nevirapine plasma concentrations in the Caucasian population.... 
Confidence intervals | Antiretroviral drugs | Hepatitis
Journal Article
Journal Article
Pharmacogenetics and Genomics, ISSN 1744-6872, 2017, Volume 27, Issue 2, pp. 81 - 82
Journal Article
Journal Article
BMC biology, ISSN 1741-7007, 2009, Volume 7, Issue 1, pp. 41 - 41
Journal Article
British Journal of Clinical Pharmacology, ISSN 0306-5251, 09/2015, Volume 80, Issue 3, pp. 581 - 588
Aims Triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan is a standard therapy for metastatic colorectal cancer (CRC). Single nucleotide... 
colorectal cancer | irinotecan | single nucleotide polymorphisms | pharmacogenetics | fluoropyrimidines | 1ST-LINE TREATMENT | LEUCOVORIN | BEVACIZUMAB | GUIDELINES | TOXICITY | FLUOROURACIL | CAPECITABINE | 5-FLUOROURACIL | FOLFOXIRI | PHARMACOLOGY & PHARMACY | EXPRESSION | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Fluorouracil - therapeutic use | Glucuronosyltransferase - genetics | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Dihydropyrimidine Dehydrogenase Deficiency - genetics | Fluorouracil - adverse effects | Colorectal Neoplasms - drug therapy | Adult | Camptothecin - administration & dosage | Female | Leucovorin - therapeutic use | Camptothecin - analogs & derivatives | Dihydropyrimidine Dehydrogenase Deficiency - etiology | Camptothecin - adverse effects | Glucuronosyltransferase - deficiency | Camptothecin - therapeutic use | Homozygote | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Heterozygote | Aged | MicroRNAs - genetics | Polymorphism, Single Nucleotide | Organoplatinum Compounds - therapeutic use | Dihydrouracil Dehydrogenase (NADP) - genetics | Organoplatinum Compounds - adverse effects | Antimitotic agents | Cancer patients | Care and treatment | Pharmacogenetics | Chemotherapy | Analysis | Colorectal cancer | Single nucleotide polymorphisms | Antineoplastic agents | Chromosomes | Cancer
Journal Article
The Journal of Antimicrobial Chemotherapy, ISSN 0305-7453, 04/2015, Volume 70, Issue 4, p. 1155
  The equilibrative nucleoside transporter 1 (ENT1) is the main protein involved in ribavirin cellular uptake. Polymorphisms at the SLC29A1 gene, encoding... 
Hepatitis | Antibiotics | Anemia | Drug therapy | Patients | Polymorphism
Journal Article
Journal of Antimicrobial Chemotherapy, ISSN 0305-7453, 09/2014, Volume 70, Issue 4, pp. 1155 - 1160
Journal Article